Literature DB >> 22872742

Role of O-(2-(18)F-fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis.

Norbert Galldiks1, Gabriele Stoffels, Christian P Filss, Marc D Piroth, Michael Sabel, Maximilian I Ruge, Hans Herzog, Nadim J Shah, Gereon R Fink, Heinz H Coenen, Karl-Josef Langen.   

Abstract

UNLABELLED: The aim of this study was to investigate the potential of O-(2-(18)F-fluoroethyl)-L-tyrosine ((18)F-FET) PET for differentiating local recurrent brain metastasis from radiation necrosis after radiation therapy because the use of contrast-enhanced MRI for this issue is often difficult.
METHODS: Thirty-one patients (mean age ± SD, 53 ± 11 y) with single or multiple contrast-enhancing brain lesions (n = 40) on MRI after radiation therapy of brain metastases were investigated with dynamic (18)F-FET PET. Maximum and mean tumor-to-brain ratios (TBR(max) and TBR(mean), respectively; 20-40 min after injection) of (18)F-FET uptake were determined. Time-activity curves were generated, and the time to peak (TTP) was calculated. Furthermore, time-activity curves of each lesion were assigned to one of the following curve patterns: (I) constantly increasing (18)F-FET uptake, (II) (18)F-FET uptake peaking early (TTP ≤ 20 min) followed by a plateau, and (III) (18)F-FET uptake peaking early (TTP ≤ 20 min) followed by a constant descent. The diagnostic accuracy of the TBR(max) and TBR(mean) of (18)F-FET uptake and the curve patterns for the correct identification of recurrent brain metastasis were evaluated by receiver-operating-characteristic analyses or Fisher exact test for 2 × 2 contingency tables using subsequent histologic analysis (11 lesions in 11 patients) or clinical course and MRI findings (29 lesions in 20 patients) as reference.
RESULTS: Both TBR(max) and TBR(mean) were significantly higher in patients with recurrent metastasis (n = 19) than in patients with radiation necrosis (n = 21) (TBR(max), 3.2 ± 0.9 vs. 2.3 ± 0.5, P < 0.001; TBR(mean), 2.1 ± 0.4 vs. 1.8 ± 0.2, P < 0.001). The diagnostic accuracy of (18)F-FET PET for the correct identification of recurrent brain metastases reached 78% using TBR(max) (area under the ROC curve [AUC], 0.822 ± 0.07; sensitivity, 79%; specificity, 76%; cutoff, 2.55; P = 0.001), 83% using TBR(mean) (AUC, 0.851 ± 0.07; sensitivity, 74%; specificity, 90%; cutoff, 1.95; P < 0.001), and 92% for curve patterns II and III versus curve pattern I (sensitivity, 84%; specificity, 100%; P < 0.0001). The highest accuracy (93%) to diagnose local recurrent metastasis was obtained when both a TBR(mean) greater than 1.9 and curve pattern II or III were present (AUC, 0.959 ± 0.03; sensitivity, 95%; specificity, 91%; P < 0.001).
CONCLUSION: Our findings suggest that the combined evaluation of the TBR(mean) of (18)F-FET uptake and the pattern of the time-activity curve can differentiate local brain metastasis recurrence from radionecrosis with high accuracy. (18)F-FET PET may thus contribute significantly to the management of patients with brain metastases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22872742     DOI: 10.2967/jnumed.112.103325

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  67 in total

Review 1.  Defining the endpoints: how to measure the efficacy of drugs that are active against central nervous system metastases.

Authors:  Alessandra Fabi; Antonello Vidiri
Journal:  Transl Lung Cancer Res       Date:  2016-12

Review 2.  The Role of Standard and Advanced Imaging for the Management of Brain Malignancies From a Radiation Oncology Standpoint.

Authors:  Robert H Press; Jim Zhong; Saumya S Gurbani; Brent D Weinberg; Bree R Eaton; Hyunsuk Shim; Hui-Kuo G Shu
Journal:  Neurosurgery       Date:  2019-08-01       Impact factor: 4.654

Review 3.  Brain metastases: neuroimaging.

Authors:  Whitney B Pope
Journal:  Handb Clin Neurol       Date:  2018

4.  The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma.

Authors:  Norbert Galldiks; Gabriele Stoffels; Christian Filss; Marion Rapp; Tobias Blau; Caroline Tscherpel; Garry Ceccon; Veronika Dunkl; Martin Weinzierl; Michael Stoffel; Michael Sabel; Gereon R Fink; Nadim J Shah; Karl-Josef Langen
Journal:  Neuro Oncol       Date:  2015-05-24       Impact factor: 12.300

Review 5.  Unsanctifying the sanctuary: challenges and opportunities with brain metastases.

Authors:  Shannon Puhalla; William Elmquist; David Freyer; Lawrence Kleinberg; Chris Adkins; Paul Lockman; John McGregor; Leslie Muldoon; Gary Nesbit; David Peereboom; Quentin Smith; Sara Walker; Edward Neuwelt
Journal:  Neuro Oncol       Date:  2015-05       Impact factor: 12.300

6.  Dual-time-point O-(2-[(18)F]fluoroethyl)-L-tyrosine PET for grading of cerebral gliomas.

Authors:  Philipp Lohmann; Hans Herzog; Elena Rota Kops; Gabriele Stoffels; Natalie Judov; Christian Filss; Norbert Galldiks; Lutz Tellmann; Carolin Weiss; Michael Sabel; Heinz Hubert Coenen; Nadim Jon Shah; Karl-Josef Langen
Journal:  Eur Radiol       Date:  2015-03-27       Impact factor: 5.315

Review 7.  Is there still a role for SPECT-CT in oncology in the PET-CT era?

Authors:  Rodney J Hicks; Michael S Hofman
Journal:  Nat Rev Clin Oncol       Date:  2012-11-13       Impact factor: 66.675

8.  Letter to the Editor: "The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline" [J Neurooncol 2014; 118:435-460].

Authors:  Karl-Josef Langen; Jörg C Tonn; Michael Weller; Norbert Galldiks
Journal:  J Neurooncol       Date:  2014-08-24       Impact factor: 4.130

9.  System a amino acid transport-targeted brain and systemic tumor PET imaging agents 2-amino-3-[(18)F]fluoro-2-methylpropanoic acid and 3-[(18)F]fluoro-2-methyl-2-(methylamino)propanoic acid.

Authors:  Weiping Yu; Jonathan McConathy; Jeffrey J Olson; Mark M Goodman
Journal:  Nucl Med Biol       Date:  2014-08-01       Impact factor: 2.408

10.  Distinguishing True Progression From Radionecrosis After Stereotactic Radiation Therapy for Brain Metastases With Machine Learning and Radiomics.

Authors:  Luke Peng; Vishwa Parekh; Peng Huang; Doris D Lin; Khadija Sheikh; Brock Baker; Talia Kirschbaum; Francesca Silvestri; Jessica Son; Adam Robinson; Ellen Huang; Heather Ames; Jimm Grimm; Linda Chen; Colette Shen; Michael Soike; Emory McTyre; Kristin Redmond; Michael Lim; Junghoon Lee; Michael A Jacobs; Lawrence Kleinberg
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-05-24       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.